The Function and Regulation of Platelet P2Y12 Receptor

被引:20
|
作者
Li, Xiaohua [1 ,2 ]
Zhang, Guoxing [3 ]
Cao, Xia [2 ]
机构
[1] First Hosp Jilin Univ, Dept Infect Dis, Changchun 130021, Jilin, Peoples R China
[2] Jilin Univ, Sch Pharm, Dept Pharmacol, Fujin Rd, Changchun 130021, Jilin, Peoples R China
[3] Ji Lin Tumor Hosp, ICU, Changchun, Peoples R China
关键词
Platelet; Inflammation; Regulation; THROMBOXANE A(2) GENERATION; ACUTE CORONARY SYNDROME; SMOOTH-MUSCLE-CELLS; P2Y(12) RECEPTOR; ADENOSINE-DIPHOSPHATE; ANTIPLATELET THERAPY; ADP RECEPTORS; SYSTEMIC INFLAMMATION; SIGNAL-TRANSDUCTION; THROMBIN GENERATION;
D O I
10.1007/s10557-021-07229-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In addition to the key role in hemostasis and thrombosis, platelets have also been wildly acknowledged as immune regulatory cells and involving in the pathogenesis of inflammation-related diseases. Since purine receptor P2Y12 plays a crucial role in platelet activation, P2Y12 antagonists such as clopidogrel, prasugrel, and ticagrelor have been widely used in cardiovascular diseases worldwide in recent decades due to their potent antiplatelet and antithrombotic effects. Meanwhile, the role of P2Y12 in inflammatory diseases has also been extensively studied. Relatively, there are few studies on the regulation of P2Y12. This review first summarizes the various roles of P2Y12 in the process of platelet activation, as well as downstream effects and signaling pathways; then introduces the effects of P2Y12 in inflammatory diseases such as sepsis, atherosclerosis, cancer, autoimmune diseases, and asthma; and finally reviews the current researches on P2Y12 regulation.
引用
收藏
页码:199 / 216
页数:18
相关论文
共 50 条
  • [41] Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
    Mousa, Shaker A.
    Jeske, Walter P.
    Fareed, Jawed
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (02) : 170 - 176
  • [42] Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice
    Golino, Paolo
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2013, 14 : S22 - S30
  • [43] Rocuronium Has a Suppressive Effect on Platelet Function via the P2Y12 Receptor Pathway In Vitro That Is Not Reversed by Sugammadex
    Murata, Yutaka
    Kawamoto, Shuji
    Fukuda, Kazuhiko
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 10
  • [44] Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate
    Cattaneo, Marco
    THROMBOSIS AND HAEMOSTASIS, 2011, 105 : S67 - S74
  • [45] P2Y12 Inhibition Suppresses Proinflammatory Platelet-Monocyte Interactions
    Rolling, Christina C.
    Sowa, Marcin A.
    Wang, Tricia T. T.
    Cornwell, MacIntosh
    Myndzar, Khrystyna
    Schwartz, Tamar
    El Bannoudi, Hanane
    Buyon, Jill
    Barrett, Tessa J.
    Berger, Jeffrey S.
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (02) : 231 - 244
  • [46] In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation
    Armstrong, P. C. J.
    Leadbeater, P. D.
    Chan, M. V.
    Kirkby, N. S.
    Jakubowski, J. A.
    Mitchell, J. A.
    Warner, T. D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (03) : 552 - 561
  • [47] The P2Y12 receptor as a target of antithrombotic drugs
    O'Connor, Stephen
    Montalescot, Gilles
    Collet, Jean-Philippe
    PURINERGIC SIGNALLING, 2011, 7 (03) : 325 - 332
  • [48] Role and recent progress of P2Y12 receptor in cancer development
    Xi, Yanni
    Min, Zhenya
    Liu, Mianxue
    Li, Xueqin
    Yuan, Zhao-hua
    PURINERGIC SIGNALLING, 2024,
  • [49] P2Y12 Receptor Modulates Sepsis-Induced Inflammation
    Liverani, Elisabetta
    Rico, Mario C.
    Tsygankov, Alexander Y.
    Kilpatrick, Laurie E.
    Kunapuli, Satya P.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (05) : 961 - 971
  • [50] Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
    Anderson, Shawn D.
    Shah, Niren K.
    Yim, Juwon
    Epstein, Benjamin J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 524 - 537